PUBLISHER: Grand View Research | PRODUCT CODE: 1588460
PUBLISHER: Grand View Research | PRODUCT CODE: 1588460
The global pneumatic nebulizers market size is expected to reach USD 1,166.74 million by 2030, registering a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has shown constant growth in the adoption of pneumatic nebulizers as home healthcare devices have been gaining popularity in recent years. Miniaturization of products and technological advancements are also boosting the adoption of home healthcare devices.
As per the Minnesota Department of Health, administration of medication through nebulizer represents a lower infection risk as compared to other aerosol-producing procedures. On the other hand, according to ISAM, aerosols from the nebulizer do not carry viral particles derived from the patient as they are generated from the fluid in the nebulized chamber, which is a non-patient source. Aerosols generated by nebulizers comprise pathogens only when the healthcare workers or patients contaminate the nebulizers. Various recommendations from institutes do not clarify whether it is appropriate to use nebulizers during the pandemic.
However, there are no known cases of passive infection due to nebulizers. Also, the risk of infection, if any, can be avoided if proper COVID-19 precautions are taken. Therefore, the pandemic affected the overall market only to a certain extent. Revolutionary technological progress is rapidly transforming the market. These expansions are producing lucrative potentials. For instance, in March 2019, Breath Technologies announced the initiation of Phase 3 BOSTON clinical study of L-CsA-i for the treatment of bronchiolitis obliterans syndrome via a drug-specific eFlow nebulizer of PARI Pharma that is under investigation.